Detection of folate receptor-positive circulating tumor cells as a biomarker for diagnosis, prognostication, and therapeutic monitoring in breast cancer

N/ACitations
Citations of this article
26Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Objectives: This study is to explore the clinical significance of folate receptor-positive circulating tumor cells (FR+CTC) in the early diagnosis and disease progress in patients with breast cancer. Methods: Folate receptor-positive circulating tumor cells was enriched from peripheral blood of the patients with immunomagnetic separation method and quantitated by folate receptor on the CTC with the ligand-targeted PCR. Results: The levels of FR+CTC were significantly higher in breast cancer patients compared with healthy controls. Detective rate of FR+CTC was decreased in 19 of 27 patients underwent the surgery in 2 weeks post-operation compared with pre-operation; statistical analysis showed the difference was significant. We also found that the combination of FR+CTC, CEA, CA125, and CA153 can significantly improve the diagnostic efficiency for breast cancer. Conclusions: This study showed the detective rate of FR+CTC is significantly increased in the patients with breast cancer, and the detective level is associated with disease progress.

Cite

CITATION STYLE

APA

Wu, Q., Zheng, H., Gu, J., Cheng, Y., Qiao, B., Wang, J., … Tong, Y. (2022). Detection of folate receptor-positive circulating tumor cells as a biomarker for diagnosis, prognostication, and therapeutic monitoring in breast cancer. Journal of Clinical Laboratory Analysis, 36(1). https://doi.org/10.1002/jcla.24180

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free